The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10293072" target="_blank" >RIV/00064203:_____/14:10293072 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/14:10293072

Výsledek na webu

<a href="http://dx.doi.org/10.1186/1471-2490-14-79" target="_blank" >http://dx.doi.org/10.1186/1471-2490-14-79</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/1471-2490-14-79" target="_blank" >10.1186/1471-2490-14-79</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy

Popis výsledku v původním jazyce

Background: It is well recognized that the presence of positive surgical margins (PSM) after radical prostatectomy (RP) adversely affects cancer specific outcomes and recent evidence from randomized trials supports the use of adjuvant radiotherapy in these cases. However, not all of the patients with PSM develop disease recurrence and the policy of adjuvant radiation could result in considerable over-treatment. We investigated the ability of early postoperative prostate specific antigen (PSA) and PSA decline rates to stratify the risk of disease progression during the first weeks after the surgery thereby allowing adequate time for planning eventual adjuvant therapy. Methods: We studied 116 consecutive patients with the finding of PSM after RP for localized prostate cancer between 2001 and 2012. No patients were treated with radiation or hormonal therapy. An intensive postoperative PSA monitoring using ultrasensitive assay started first at day 14 after the surgery, then at day 30, 60,

Název v anglickém jazyce

The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy

Popis výsledku anglicky

Background: It is well recognized that the presence of positive surgical margins (PSM) after radical prostatectomy (RP) adversely affects cancer specific outcomes and recent evidence from randomized trials supports the use of adjuvant radiotherapy in these cases. However, not all of the patients with PSM develop disease recurrence and the policy of adjuvant radiation could result in considerable over-treatment. We investigated the ability of early postoperative prostate specific antigen (PSA) and PSA decline rates to stratify the risk of disease progression during the first weeks after the surgery thereby allowing adequate time for planning eventual adjuvant therapy. Methods: We studied 116 consecutive patients with the finding of PSM after RP for localized prostate cancer between 2001 and 2012. No patients were treated with radiation or hormonal therapy. An intensive postoperative PSA monitoring using ultrasensitive assay started first at day 14 after the surgery, then at day 30, 60,

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BMC Urology

ISSN

1471-2490

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

neuveden

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

—

Kód UT WoS článku

000345463700001

EID výsledku v databázi Scopus

—